loading
前日終値:
$3.25
開ける:
$3.3
24時間の取引高:
2.56M
Relative Volume:
0.53
時価総額:
$864.32M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-11.77
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
+12.84%
1か月 パフォーマンス:
+34.49%
6か月 パフォーマンス:
+61.52%
1年 パフォーマンス:
+189.04%
1日の値動き範囲:
Value
$3.22
$3.31
1週間の範囲:
Value
$2.87
$3.31
52週間の値動き範囲:
Value
$0.80
$3.31

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
名前
Akebia Therapeutics Inc
Name
セクター
Healthcare (1170)
Name
電話
617-871-2098
Name
住所
245 FIRST STREET, CAMBRIDGE, MA
Name
職員
181
Name
Twitter
@akebiatx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
AKBA's Discussions on Twitter

AKBA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
3.2909 766.90M 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.10 50.54B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
171.19 74.02B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.86 4.22M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.96 45.82B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.27 20.31B 16.54B -1.64B 749.00M -1.45

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-28 開始されました Leerink Partners Outperform
2025-04-01 開始されました Jefferies Buy
2023-11-29 再開されました BTIG Research Buy
2023-08-28 アップグレード H.C. Wainwright Neutral → Buy
2023-05-31 アップグレード Piper Sandler Neutral → Overweight
2022-03-31 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-31 ダウングレード Mizuho Buy → Neutral
2022-03-31 ダウングレード Needham Buy → Hold
2022-03-31 ダウングレード Piper Sandler Overweight → Neutral
2021-03-08 開始されました Cantor Fitzgerald Overweight
2021-01-29 ダウングレード JP Morgan Neutral → Underweight
2019-11-14 繰り返されました Needham Buy
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-07-11 繰り返されました H.C. Wainwright Buy
2019-05-02 開始されました JP Morgan Overweight
2019-03-20 開始されました Citigroup Neutral
2018-09-07 再開されました Morgan Stanley Equal-Weight
2018-08-10 繰り返されました Needham Buy
2018-06-06 繰り返されました H.C. Wainwright Buy
2017-12-19 開始されました Piper Jaffray Overweight
2017-12-07 開始されました BTIG Research Buy
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-07-10 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました Needham Buy
2016-12-27 繰り返されました H.C. Wainwright Buy
2016-12-20 繰り返されました JMP Securities Mkt Outperform
2016-11-15 開始されました Aegis Capital Buy
2016-09-29 開始されました Brean Capital Buy
2016-03-16 繰り返されました Needham Buy
2016-01-21 開始されました Credit Suisse Neutral
すべてを表示

Akebia Therapeutics Inc (AKBA) 最新ニュース

pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AKBA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan

Jun 02, 2025
pulisher
May 28, 2025

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 27, 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan

May 27, 2025
pulisher
May 25, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 25, 2025
pulisher
May 24, 2025

Northern Trust Corp Has $3.20 Million Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 24, 2025
pulisher
May 20, 2025

Akebia Therapeutics stock soars to 52-week high of $2.91 By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Akebia Therapeutics at H.C. Wainwright Conference: Vafseo’s Strategic Launch By Investing.com - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

Akebia Therapeutics stock soars to 52-week high of $2.91 - Investing.com Australia

May 20, 2025
pulisher
May 18, 2025

Certain Common Stock of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Stock Options of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Rights of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Warrants of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 16, 2025

Price T Rowe Associates Inc. MD Has $263,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 16, 2025
pulisher
May 15, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Voya Investment Management LLC - Defense World

May 15, 2025
pulisher
May 14, 2025

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Raymond James Financial Inc. Invests $85,000 in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 14, 2025
pulisher
May 13, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire

May 13, 2025
pulisher
May 10, 2025

Akebia projects Vafseo rollout to double patient access by Q4 2025 - MSN

May 10, 2025
pulisher
May 10, 2025

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

May 10, 2025
pulisher
May 10, 2025

Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Mariner LLC Invests $28,000 in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 10, 2025
pulisher
May 09, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Acquired by MetLife Investment Management LLC - Defense World

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics (NASDAQ:AKBA) Sets New 52-Week High After Strong Earnings - Defense World

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and Strategic Market Penetration - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Stock Traders Purchase Large Volume of Akebia Therapeutics Call Options (NASDAQ:AKBA) - Defense World

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Reports Strong Q1 2025 Performance - TipRanks

May 09, 2025
pulisher
May 08, 2025

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 08, 2025
pulisher
May 08, 2025

Transcript : Akebia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics (AKBA) Sees Strong Q1 Revenue Growth Fueled by Vafseo - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Wells Fargo & Company MN Raises Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Akebia Therapeutics beats Q1 2025 estimates, stock surges - Investing.com Australia

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Akebia (AKBA) Surpasses Revenue Expectations with Strong Vafseo Debut | AKBA Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics Inc Q1 2025 Earnings: EPS of $0.04, Revenue Surges to $57.3 Million, Beating Estimates - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by Barclays PLC - Defense World

May 08, 2025
pulisher
May 07, 2025

Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result - Yahoo Finance

May 07, 2025

Akebia Therapeutics Inc (AKBA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Akebia Therapeutics Inc (AKBA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Burke Steven Keith
SVP, Chief Medical Officer
Mar 03 '25
Sale
1.83
7,144
13,074
809,090
$8.425
price down icon 3.28%
drug_manufacturers_specialty_generic RDY
$14.62
price down icon 0.81%
$124.86
price down icon 0.01%
drug_manufacturers_specialty_generic HCM
$14.21
price up icon 2.99%
$324.39
price down icon 0.70%
$17.29
price up icon 0.03%
大文字化:     |  ボリューム (24 時間):